MAMichael Asamoah-Boaheng

Michael Asamoah-Boaheng

*This is an algorithmically generated author record based on publicly available information.

Michael Asamoah-Boaheng has a total of 97 co-authors. Here are the top co-authors by number of shared publications:

  • Brian Grunau

    University of British Columbia

    11 shared publications
  • Mohammad Ehsanul Karim

    Centre for Health Evaluation and Outcome Sciences, St. Paul’s Hospital, Vancouver, British Columbia, Canada. School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada

    9 shared publications
  • Ana Citlali Marquez

    Public Health Laboratory, British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada

    8 shared publications
  • David M. Goldfarb

    14 British Columbia Children’s Hospital, Vancouver, Canada

    8 shared publications
  • Tracy Kirkham

    Occupational Cancer Research Centre, Ontario Health, Toronto, Ontario, Canada. Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada

    8 shared publications
  • Vilte Barakauskas

    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada

    8 shared publications

Latest Publications

  • Open Access

    Immunogenicity of bivalent versus monovalent mRNA booster vaccination among adult paramedics in Canada who had received three prior mRNA wild-type doses

    by Michael Asamoah-Boaheng, David M. Goldfarb, Iryna Kayda, Justin Yap, Tracy Kirkham, Mohammad Ehsanul Karim, Paul Demers, Jeffrey M. Copp, Brian Grunau

    Introduction. Comparative immunogenicity from different mRNA booster vaccines (directed at WT, BA.1 or BA.4/5 antigens) remains unclear. Methods. We included blood samples from adult paramedics who received three mRNA WT-directed vaccines plus a fourth dose of the following: (1) WT monovalent, (2) Moderna BA.1-WT bivalent or (3) Pfizer BA.4/5 WT bivalent vaccine. The primary outcome was angiotensin-converting enzyme 2 (ACE2) inhibition to BA.4/5 antigen. We used optimal pair matching (using age, sex-at-birth, preceding SARS-CoV-2 infection and fourth vaccine-to-blood collection interval) to create balanced groups to individually compare each vaccine type to each other vaccine (overall, within subgroups defined by SARS-CoV-2 infection and after combining BA.1 and BA.4/5 cases). We compared outcomes with the Wilcoxon matched-pairs signed rank test. Results. Overall, 158 paramedics (mean age 45 years) were included. ACE2 inhibition was higher for BA.1 compared to WT (P=0.002); however, no difference was detected between BA.4/5 vs. WT or BA.1 vs. BA.4/5. Among cases with preceding SARS-CoV-2, there were no detected between-group differences. Among cases without preceding SARS-CoV-2, the only detected difference was BA.1>WT (P=0.003). BA.1 and BA.4/5 cases combined had higher ACE2 inhibition than WT (P=0.003). Conclusion. Omicron-directed vaccines appear to improve Omicron-specific immunogenicity; however, this appears limited to SARS-CoV-2-naive individuals.

  • Open Access

    Immunogenicity of bivalent versus monovalent mRNA booster vaccination among adult paramedics in Canada who had received three prior mRNA wild-type doses

    by Michael Asamoah-Boaheng, David M. Goldfarb, Iryna Kayda, Justin Yap, Tracy Kirkham, Mohammad Ehsanul Karim, Paul Demers, Jeffrey M. Copp, Brian Grunau

    Introduction Comparative immunogenicity from different mRNA booster vaccines (directed at wild-type [WT], BA.1, or BA.4/5 antigens) remains unclear. Methods We included blood samples from adult paramedics who received three mRNA WT-directed vaccines plus a fourth dose of: (1) WT monovalent; (2) Moderna BA.1-WT bivalent; or (3) Pfizer BA.4/5-WT bivalent vaccine. The primary outcome was angiotensin-converting enzyme 2 (ACE-2) inhibition to BA.4/5 antigen. We used optimal pair matching (using age, sex-at-birth, preceding SARS-CoV-2 infection, and fourth vaccine-to-blood collection interval) to create balanced groups to individually compare each vaccine type to each other vaccine (overall, within subgroups defined by SARS-CoV-2 infection, and after combining BA.1 and BA.4/5 cases). We compared outcomes with Wilcoxon matched pairs signed rank test. Results Overall, 158 paramedics (mean age 45 years) were included. ACE-2 inhibition was higher for BA.1 compared to WT (p=0.002); however, no difference was detected between BA.4/5 vs. WT, or BA.1 vs BA.4/5. Among cases with preceding SARS-CoV-2, there were no between-group differences. Among cases without preceding SARS-CoV-2, the only difference was BA.1 > WT (p=0.003). BA.1 and BA.4/5 cases combined had higher ACE2 inhibition than WT (p = 0.003). Conclusion Omicron-directed vaccines appear to improve Omicron-specific immunogenicity; however, this appears limited to SARS-CoV-2-naïve individuals.

  • Canada’s approach to SARS-CoV-2 sero-surveillance: Lessons learned for routine surveillance and future pandemics

    by Sheila F. O’bRien, Michael Asamoah-Boaheng, Brian Grunau, Mel Krajden, David L. Buckeridge, David M. Goldfarb, Maureen Anderson, Marc Germain, Patrick Brown, Derek R. Stein, et al.

    In Canada’s federated healthcare system, 13 provincial and territorial jurisdictions have independent responsibility to collect data to inform health


  • Open Access

    Immunogenicity of bivalent versus monovalent mRNA booster vaccination among adult paramedics in Canada who had received three prior mRNA wild-type doses

    by Michael Asamoah-Boaheng, David M. Goldfarb, Iryna Kayda, Justin Yap, Tracy Kirkham, Mohammad Ehsanul Karim, Paul Demers, Jeffrey M. Copp, Brian Grunau

    Introduction Comparative immunogenicity from different mRNA booster vaccines (directed at wild-type [WT], BA.1, or BA.4/5 antigens) remains unclear. Methods We included blood samples from adult paramedics who received three mRNA WT-directed vaccines plus a fourth dose of: (1) WT monovalent; (2) Moderna BA.1-WT bivalent; or (3) Pfizer BA.4/5-WT bivalent vaccine. The primary outcome was angiotensin-converting enzyme 2 (ACE-2) inhibition to BA.4/5 antigen. We used optimal pair matching (using age, sex-at-birth, preceding SARS-CoV-2 infection, and fourth vaccine-to-blood collection interval) to create balanced groups to individually compare each vaccine type to each other vaccine (overall, within subgroups defined by SARS-CoV-2 infection, and after combining BA.1 and BA.4/5 cases). We compared outcomes with Wilcoxon matched pairs signed rank test. Results Overall, 158 paramedics (mean age 45 years) were included. ACE-2 inhibition was higher for BA.1 compared to WT (p=0.002); however, no difference was detected between BA.4/5 vs. WT, or BA.1 vs BA.4/5. Among cases with preceding SARS-CoV-2, there were no between-group differences. Among cases without preceding SARS-CoV-2, the only difference was BA.1 > WT (p=0.003). BA.1 and BA.4/5 cases combined had higher ACE2 inhibition than WT (p = 0.003). Conclusion Omicron-directed vaccines appear to improve Omicron-specific immunogenicity; however, this appears limited to SARS-CoV-2-naïve individuals.

  • Open Access

    Investigating the Antibody Imprinting Hypothesis among Canadian Paramedics after SARS-CoV-2 Omicron Variant Circulation

    by Michael Asamoah-Boaheng, Brian Grunau, Mohammad Ehsanul Karim, Iryna Kayda, Justin Yap, Katherine Bessai, David M. Goldfarb

    Recent research has highlighted the Omicron variant’s capacity to evade immune protection conferred by wild-type (WT) mRNA vaccines. Despite this observation, the potential involvement of antigenic sin phenomena remains unclear. Our hypothesis posited that a greater number of prior WT vaccine doses might lead to reduced anti-Omicron neutralization Abs following Omicron infection. To investigate this, we analyzed blood samples from human participants in the COVID-19 Occupational Risk, Seroprevalence, and Immunity among Paramedics (CORSIP) study who had received at least one WT mRNA vaccine before contracting Omicron. The exposure variable was the number of WT mRNA vaccines administered, and the outcome was the angiotensin-converting enzyme 2 (ACE-2) percent inhibition specific to the BA.4/BA.5 Omicron Ag. Contrary to expectations, our findings revealed that more WT-based vaccines were associated with an enhanced Omicron-specific immune response.


  • Open Access

    The relationship between the number of COVID-19 vaccines and infection with Omicron ACE2 inhibition at 18-months post initial vaccination in an adult cohort of Canadian paramedics

    by Justin Yap, Iryna Kayda, Michael Asamoah-Boaheng, Scott Haig, Tracy Kirkham, Sheldon Cheskes, Paul Demers, David Goldfarb, Brian Grunau

    The coronavirus disease 2019 (COVID-19) pandemic, caused by the SARS-CoV-2 virus, has rapidly evolved since late 2019, due to highly transmissible Omicron variants. While most Canadian paramedics have received COVID-19 vaccination, the optimal ongoing vaccination strategy is unclear. We investigated neutralizing antibody (NtAb) response against wild-type (WT) Wuhan Hu-1 and Omicron BA.4/5 lineages based on the number of doses and past SARS-CoV-2 infection, at 18 months post initial vaccination (with a Wuhan Hu-1 platform mRNA vaccine [BNT162b2 or mRNA-1273}). Demographic information, previous COVID-19 vaccination, infection history, and blood samples were collected from paramedics 18 months post initial mRNA COVID-19 vaccine dose. Outcome measures were ACE2 percent inhibition against Omicron BA.4/5 and WT antigens. We compared outcomes based on number of vaccine doses (two vs. three) and previous SARS-CoV-2 infection status, using the Mann-Whitney U test. Of 657 participants, the median age was 40 years (IQR 33-50) and 251 (42%) were females. Overall, median percent inhibition to BA.4/5 and WT was 71.61% (IQR 39.44-92.82) and 98.60% (IQR 83.07-99.73), respectively. Those with a past SARS-CoV-2 infection had a higher median percent inhibition to BA.4/5 and WT, when compared to uninfected individuals overall and when stratified by two or three vaccine doses. When comparing two vs. three WT vaccine doses among SARS-CoV-2 negative participants, we did not detect a difference in BA.4/5 percent inhibition, but there was a difference in WT percent inhibition. Among those with previous SARS-CoV-2 infection(s), when comparing two vs. three WT vaccine doses, there was no observed difference between groups. These findings demonstrate that additional Wuhan Hu-1 platform mRNA vaccines did not improve NtAb response to BA.4/5, but prior SARS-CoV-2 infection enhances NtAb response.

  • Open Access

    The relationship between the number of COVID-19 vaccines and infection with Omicron ACE2 inhibition at 18-months post initial vaccination in an adult cohort of Canadian paramedics

    by Justin Yap, Iryna Kayda, Michael Asamoah-Boaheng, Scott Haig, Tracy Kirkham, Sheldon Cheskes, Paul Demers, David Goldfarb, Brian E. Grunau

    The coronavirus disease 2019 (COVID-19) pandemic, caused by the SARS-CoV-2 virus, has rapidly evolved since late 2019, due to highly transmissible Omicron variants. While most Canadian paramedics have received COVID-19 vaccination, the optimal ongoing vaccination strategy is unclear. We investigated neutralizing antibody (NtAb) response against wild-type (WT) Wuhan Hu-1 and Omicron BA.4/5 lineages based on the number of doses and past SARS-CoV-2 infection, at 18 months post-initial vaccination (with a Wuhan Hu-1 platform mRNA vaccine [BNT162b2 or mRNA-1273]). Demographic information, previous COVID-19 vaccination, infection history, and blood samples were collected from paramedics 18 months post-initial mRNA COVID-19 vaccine dose. Outcome measures were ACE2 percent inhibition against Omicron BA.4/5 and WT antigens. We compared outcomes based on number of vaccine doses (two vs. three) and previous SARS-CoV-2 infection status, using the Mann-Whitney U test. Of 657 participants, the median age was 40 years (IQR 33–50) and 251 (42 %) were females. Overall, median percent inhibition to BA.4/5 and WT was 71.61 % (IQR 39.44–92.82) and 98.60 % (IQR 83.07–99.73), respectively. Those with a past SARS-CoV-2 infection had a higher median percent inhibition to BA.4/5 and WT, when compared to uninfected individuals overall and when stratified by two or three vaccine doses. When comparing two vs. three WT vaccine doses among SARS-CoV-2 negative participants, we did not detect a difference in BA.4/5 percent inhibition, but there was a difference in WT percent inhibition. Among those with previous SARS-CoV-2 infection(s), when comparing two vs. three WT vaccine doses, there was no observed difference between groups. These findings demonstrate that additional Whttps://www.covid19immunitytaskforce.ca/citf-databank/#accessing https://www.covid19immunitytaskforce.ca/citf-databank/#accessinguhan Hu-1 platform mRNA vaccines did not improve NtAb response to BA.4/5, but prior SARS-CoV-2 infection enhances NtAb response.

  • Open Access

    Eleven-month SARS-CoV-2 binding antibody decay, and associated factors, among mRNA vaccinees: implications for booster vaccination

    by Michael Asamoah-Boaheng, Brian Grunau, Scott Haig, Mohammad Ehsanul Karim, Tracy Kirkham, Pascal M. Lavoie, Sadaf Sediqi, Steven J. Drews, Sheila F. O'BRien, Vilte Barakauskas, et al.

    Background. We examined the 11 month longitudinal antibody decay among two-dose mRNA vaccinees, and identified factors associated with faster decay. Methods. The study included samples from the COVID-19 Occupational Risk, Seroprevalence and Immunity among Paramedics (CORSIP) longitudinal observational study of paramedics in Canada. Participants were included if they had received two mRNA vaccines without prior SARS-CoV-2 infection and provided two blood samples post-vaccination. The outcomes of interest were quantitative SARS-CoV-2 antibody concentrations. We employed spaghetti and scatter plots (with kernel-weighted local polynomial smoothing curve) to describe the trend of the antibody decay over 11 months post-vaccine and fit a mixed effect exponential decay model to examine the loss of immunogenicity and factors associated with antibody waning over time. Results. This analysis included 652 blood samples from 326 adult paramedics. Total anti-spike antibody levels peaked on the twenty-first day (antibody level 9042 U ml−1) after the second mRNA vaccine dose. Total anti-spike antibody levels declined thereafter, with a half-life of 94 [95 % CI: 70, 143] days, with levels plateauing at 295 days (antibody level 1021 U ml−1). Older age, vaccine dosing interval Conclusion. Antibody levels declined after the initial mRNA series with a half-life of 94 days, plateauing at 295 days. These findings may inform the timing of booster vaccine doses and identifying individuals with faster antibody decay.


  • The Association of Post-COVID-19–Related Symptoms and Preceding Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Fully Vaccinated Paramedics in Canada

    by Michael Asamoah-Boaheng, Brian Grunau, Mohammad Ehsanul Karim, Tracy L Kirkham, Paul A Demers, Chris MacDonald, David M Goldfarb

    This study investigated the association between previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and risk of symptoms associated with post-COVID conditions among fully vaccinated paramedics in Canada. We included vaccinated paramedics who provided blood sample and questionnaire data on the same date during the study period. We examined the presence of symptoms associated with post-COVID conditions and depression severity against prior SARS-CoV-2 infection categories. Compared to the “no previous SARS-CoV-2 infection” group, there was no detected association between known prior SARS-CoV-2 infection (odds ratio [OR], 1.42 [95% confidence interval {CI}, 0.96–2.09]), nor unknown prior SARS-CoV-2 infection (OR, 0.54 [95% CI, 0.29–1.00]), and the presence of symptoms associated with post-COVID conditions.


  • Open Access

    The relationship between the number of COVID-19 vaccines and infection with Omicron ACE2 inhibition at 18-months post initial vaccination in an adult cohort of Canadian paramedics

    by Justin Yap, Iryna Kayda, Michael Asamoah-Boaheng, Scott Haig, Tracy Kirkham, Sheldon Cheskes, Paul Demers, David Goldfarb, Brian Grunau

    The coronavirus disease 2019 (COVID-19) pandemic, caused by the SARS-CoV-2 virus, has rapidly evolved since late 2019, due to highly transmissible Omicron variants. While most Canadian paramedics have received COVID-19 vaccination, the optimal ongoing vaccination strategy is unclear. We investigated neutralizing antibody (NtAb) response against wild-type (WT) Wuhan Hu-1 and Omicron BA.4/5 lineages based on the number of doses and past SARS-CoV-2 infection, at 18 months post initial vaccination (with a Wuhan Hu-1 platform mRNA vaccine [BNT162b2 or mRNA-1273}). Demographic information, previous COVID-19 vaccination, infection history, and blood samples were collected from paramedics 18 months post initial mRNA COVID-19 vaccine dose. Outcome measures were ACE2 percent inhibition against Omicron BA.4/5 and WT antigens. We compared outcomes based on number of vaccine doses (two vs. three) and previous SARS-CoV-2 infection status, using the Mann-Whitney U test. Of 657 participants, the median age was 40 years (IQR 33-50) and 251 (42%) were females. Overall, median percent inhibition to BA.4/5 and WT was 71.61% (IQR 39.44-92.82) and 98.60% (IQR 83.07-99.73), respectively. Those with a past SARS-CoV-2 infection had a higher median percent inhibition to BA.4/5 and WT, when compared to uninfected individuals overall and when stratified by two or three vaccine doses. When comparing two vs. three WT vaccine doses among SARS-CoV-2 negative participants, we did not detect a difference in BA.4/5 percent inhibition, but there was a difference in WT percent inhibition. Among those with previous SARS-CoV-2 infection(s), when comparing two vs. three WT vaccine doses, there was no observed difference between groups. These findings demonstrate that additional Wuhan Hu-1 platform mRNA vaccines did not improve NtAb response to BA.4/5, but prior SARS-CoV-2 infection enhances NtAb response.